Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Bárbara Emoingt Furtado"'
Autor:
Igor Age Kos, Faissal Nemer Hajar, Gustavo Sarot Pereira da Cunha, Claudia Corte, Luisa Augusto Furlan, André Santa Maria, Douglas Valverde, Bárbara Emoingt Furtado, Miguel Morita Fernandes-Silva, Valderilio Feijó Azevedo
Publikováno v:
Vaccines, Vol 12, Iss 6, p 581 (2024)
Objective: Brazil was strongly affected by the COVID-19 pandemic. Its continental dimension and socio-demographic characteristics pose challenges to distribution and accessibility, making vaccination programs challenging. The objectives of the study
Externí odkaz:
https://doaj.org/article/f64611ae69684a90adda07ca0b5dc08e
Autor:
Eliana Nogueira Castro De Barros, Altacilio Aparecido Nunes, Ariane De Jesus Lopes De Abreu, Bárbara Emoingt Furtado, Otavio Cintra, Monica Act Cintra, Eduardo Barbosa Coelho
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 1, Pp 61-69 (2020)
Objective: We described pertussis epidemiological trends in Brazil between 2010 and 2015. We also assessed tetanus, diphtheria and acellular pertussis (Tdap) vaccine coverage among pregnant women from 2014, the year of the introduction of Tdap matern
Externí odkaz:
https://doaj.org/article/bcdea8a0398040aaa59efd6be2e107ae
Autor:
Eduardo Barbosa Coelho, Anderson Soares da Silva, Bárbara Emoingt Furtado, Eliana Nc de Barros, Ariane de Jesus Lopes de Abreu, Altacílio Aparecido Nunes
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
article-version (VoR) Version of Record
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
We aimed to describe the impact of pertussis on adolescents, adults, and older adults over 2007–2018 in selected Latin American countries by reviewing the literature. We searched the Medline, Embase, Scopus, LILACS, Scielo, Google Scholar, CAPES Jo
Autor:
Patricia Mouta Nunes de Oliveira, Daniela P. Mendes-de-Almeida, Victor Bertollo Gomes Porto, Catherine Crespo Cordeiro, Gabriellen Vitiello Teixeira, Renata Saraiva Pedro, Paulo Roberto Gomes Takey, Letícia Kegele Lignani, Janaína Reis Xavier, Vitor Cardoso Doria da Gama, Luiz Amorim Filho, Bárbara Emoingt Furtado, André Santa Maria, Tiago Dahrug Barros, Livia Neves Waite Freitas, Tainá dos Santos Pereira, Debora Lima Abreu, Michael Bernardes Ramos, Caroline Gabe, Donald Arnold, James William Smith, Ishac Nazy, Maria de Lourdes de Sousa Maia
Publikováno v:
Vaccine. 40(33)
Describe a case series of vaccine-induced immune thrombotic thrombocytopenia (VITT) after COVID-19 vaccination in Brazil that included ChAdOx1 nCoV-19, Ad26.COV2.S and BNT162b2 vaccines, describing their clinical and laboratory characteristics.Descri
Autor:
Altacílio Aparecido Nunes, Bárbara Emoingt Furtado, Monica Act Cintra, Eliana Nogueira Castro de Barros, Eduardo Barbosa Coelho, Otavio Cintra, Ariane de Jesus Lopes de Abreu
Publikováno v:
Human Vaccines & Immunotherapeutics
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Objective: We described pertussis epidemiological trends in Brazil between 2010 and 2015. We also assessed tetanus, diphtheria and acellular pertussis (Tdap) vaccine coverage among pregnant women from 2014, the year of the introduction of Tdap matern
Autor:
Kos, Igor Age, Hajar, Faissal Nemer, Sarot Pereira da Cunha, Gustavo, Corte, Claudia, Furlan, Luisa Augusto, Santa Maria, André, Valverde, Douglas, Emoingt Furtado, Bárbara, Morita Fernandes-Silva, Miguel, Feijó Azevedo, Valderilio
Publikováno v:
Vaccines; Jun2024, Vol. 12 Issue 6, p581, 13p
Autor:
Meeraus W; Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK. Electronic address: wilhelmine.meeraus@astrazeneca.com., Stuurman AL; Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK; P95 Epidemiology & Pharmacovigilance, Leuven, Belgium., Durukal I; Real World Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Conde-Sousa E; Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK; P95 Epidemiology & Pharmacovigilance, Leuven, Belgium., Lee A; Medical and Payor Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Cambridge, UK., Maria AS; Evidence Generation, AstraZeneca, São Paulo, Brazil., Furtado BE; Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, São Paulo, Brazil., Ouwens M; Medical and Payor Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Mölndal, Sweden., Gray CM; Real World Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Valverde DA; Techtrials Healthcare Data Science, São Paulo, Brazil., da Silva HG; Formerly BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK., Taylor S; Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK.
Publikováno v:
Vaccine [Vaccine] 2023 Oct 06; Vol. 41 (42), pp. 6366-6378. Date of Electronic Publication: 2023 Sep 12.
Autor:
Mouta Nunes de Oliveira P; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil. Electronic address: Patricia.mouta@bio.fiocruz.br., Mendes-de-Almeida DP; Department of Hematology, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil; Division of Molecular Carcinogenesis, Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil; Division of Epidemiology, Department of Pediatrics, University of Minnesota, Minneapolis, United States of America., Bertollo Gomes Porto V; General Coordination of the National Immunization Program/National Immunization Program/ Brazilian Ministry of Health, Brazil., Crespo Cordeiro C; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Vitiello Teixeira G; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Saraiva Pedro R; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Roberto Gomes Takey P; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Kegele Lignani L; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Reis Xavier J; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Cardoso Doria da Gama V; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Amorim Filho L; Hemorio , Rio de Janeiro, Brazil., Emoingt Furtado B; AstraZeneca Brasil, Brazil., Santa Maria A; AstraZeneca Brasil, Brazil., Dahrug Barros T; General Coordination of the National Immunization Program/National Immunization Program/ Brazilian Ministry of Health, Brazil., Neves Waite Freitas L; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Dos Santos Pereira T; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Lima Abreu D; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Bernardes Ramos M; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil., Gabe C; Doctoral Program in Medicine at the Faculty of Medicine of the University of São Paulo, Brazil., Arnold D; McMaster Platelet Immunology Laboratory, Canada., William Smith J; McMaster Platelet Immunology Laboratory, Canada., Nazy I; McMaster Platelet Immunology Laboratory, Canada., Lourdes de Sousa Maia M; Institute of Technology in Immunobiologicals/Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil.
Publikováno v:
Vaccine [Vaccine] 2022 Aug 05; Vol. 40 (33), pp. 4788-4795. Date of Electronic Publication: 2022 Jun 16.